Erschienen in:
01.06.2021 | Anaphylaxis and Drug Allergy (BT Kelly and M Castells, Section Editors)
Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis
verfasst von:
Joana Caiado, Mariana C. Castells
Erschienen in:
Current Allergy and Asthma Reports
|
Ausgabe 6/2021
Einloggen, um Zugang zu erhalten
Abstract
Hypersensitivity reactions (HSRs) to antineoplastic drugs are increasing due to the expanding use of classical and new drugs in a wide variety of malignancies.
Purpose of Review
The goal of this review is to provide current best practices in the diagnosis and management of HSRs based on data and evidence.
Recent Findings
A plethora of studies have provided evidence of the safety and efficacy of rapid drug desensitizations (RDD) to allow for the reintroduction of antineoplastic drugs following an HSR, based on risk stratification. Recently described biomarkers such as basophil activation test, total IgE, BRCA genotyping, and serum IL-6 can aid in guiding improved precision desensitization protocols. Personalized premedication regimens and protocols have improved RDD safety and outcomes.
Summary
RDD allows for the continued use of chemotherapeutic drugs without impaired drug efficacy. RDD represents the best approach to maintain cancer patients on their most effective treatments.